Although platinum-based agents and redox-targeted therapies are not standard in PC management, their potential role in genetically defined subgroups with altered GSTM5 function, as well as the combination with demethylating agents, merits further investigation in preclinical and translational studies [21,30]. This evidence concerns the gene GSTM5 and pachyonychia congenita.